In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will MorphoSys Trade Profitability for More Products, More Opportunities, and More Risk?

Executive Summary

Morphosys is a rare biotech company in that it is both an R&D driven enterprise and is profitable at the same time, thanks mostly to a variety of antibody discovery deals it has signed over the years with pharmaceutical partners. As the company brings more product candidates into the clinic will its profitability become a strategic liability, imposing limits on how much it can spend to drive products forward?
Advertisement

Related Content

MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans
MorphoSys: Accelerating The Long Transformation
MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs
Profitable MorphoSys Proves Value of Technology Partnership Model
MorphoSys Fills Out Pipeline With Xencor Deal
MorphoSys Fills Out Pipeline With Xencor Deal
Profitability: A Mixed Blessing for Celltech

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel